Last reviewed · How we verify
Darvocet then placebo then opana
Darvocet then placebo then opana is a Opioid analgesic Small molecule drug developed by University of Rochester. It is currently FDA-approved for Moderate to severe pain (trial comparison study). Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug.
This is a study comparing three opioid pain medications: Darvocet (propoxyphene/acetaminophen), placebo, and Opana (oxymorphone), to evaluate their relative efficacy and safety in pain management.
This is a study comparing three opioid pain medications: Darvocet (propoxyphene/acetaminophen), placebo, and Opana (oxymorphone), to evaluate their relative efficacy and safety in pain management. Used for Moderate to severe pain (trial comparison study).
At a glance
| Generic name | Darvocet then placebo then opana |
|---|---|
| Also known as | opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug |
| Sponsor | University of Rochester |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Darvocet and Opana are both opioid analgesics that bind to mu-opioid receptors in the central nervous system to reduce pain perception. This appears to be a clinical trial design comparing an older opioid (Darvocet), a placebo control, and a more potent opioid (Opana) to assess pain relief outcomes and tolerability.
Approved indications
- Moderate to severe pain (trial comparison study)
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Respiratory depression
Key clinical trials
- Lumbar Stenosis Outcomes Research II (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darvocet then placebo then opana CI brief — competitive landscape report
- Darvocet then placebo then opana updates RSS · CI watch RSS
- University of Rochester portfolio CI
Frequently asked questions about Darvocet then placebo then opana
What is Darvocet then placebo then opana?
How does Darvocet then placebo then opana work?
What is Darvocet then placebo then opana used for?
Who makes Darvocet then placebo then opana?
Is Darvocet then placebo then opana also known as anything else?
What drug class is Darvocet then placebo then opana in?
What development phase is Darvocet then placebo then opana in?
What are the side effects of Darvocet then placebo then opana?
What does Darvocet then placebo then opana target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor
- Manufacturer: University of Rochester — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain (trial comparison study)
- Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug
- Compare: Darvocet then placebo then opana vs similar drugs
- Pricing: Darvocet then placebo then opana cost, discount & access